Survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan.

<h4>Background</h4>We aimed to provide real-world information on survival, health care resource utilization (HCRU), and expenditures related to various first lines of therapy (1LOTs) in newly diagnosed multiple myeloma (NDMM) patients who were transplant ineligible (TI).<h4>Patient...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chih-Ning Cheng, Shang-Yi Huang, Pei-Wen Lien, Shih-Ting Huang, Fang-Ju Lin
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/3fa55435c6784a3ea480b905293d03fe
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3fa55435c6784a3ea480b905293d03fe
record_format	dspace
spelling	oai:doaj.org-article:3fa55435c6784a3ea480b905293d03fe2021-12-02T20:05:30ZSurvival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan.1932-620310.1371/journal.pone.0252124https://doaj.org/article/3fa55435c6784a3ea480b905293d03fe2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0252124https://doaj.org/toc/1932-6203<h4>Background</h4>We aimed to provide real-world information on survival, health care resource utilization (HCRU), and expenditures related to various first lines of therapy (1LOTs) in newly diagnosed multiple myeloma (NDMM) patients who were transplant ineligible (TI).<h4>Patients and methods</h4>From the Taiwan National Health Insurance Database (2008-2016), we identified 1,511 NDMM-TI patients who had received 1LOT since June 2012. We categorized 1LOT regimens into four groups: bortezomib (V)+thalidomide (T), V, T, and non-V/T. Patients' characteristics were collected. The overall survival (OS), event-free survival (EFS), frequencies of HCRU (hospitalization, visiting outpatient and emergency departments), and related expenditures within one year after commencement of the 1LOT were evaluated and compared.<h4>Results</h4>The mean age of the included patients was 71.3 (SD 10.7) years, and 40.4% of patients had a CCI score ≥3. Most patients (747; 49.4%) were in the V+T group and, after adjusting for covariates, had a significantly longer OS (median, 22.2 months) and EFS (9.1 months) than those in the T group (12.6 and 4.5 months, respectively) and the non-V/T group (12.2 and 3.2 months, respectively), but they were mostly comparable with patients in the V group (23.8 and 6.6 months, respectively). Compared to those in the V+T group, patients in the T and non-V/T groups had 29% and 39% fewer outpatient visits and 15% and 24% lower total expenditure, respectively.<h4>Conclusion</h4>Our real-world data consolidate evidence for the effectiveness of bortezomib-containing regimens as the 1LOT in NDMM-TI patients at the expense of more outpatient visits and higher total costs.Chih-Ning ChengShang-Yi HuangPei-Wen LienShih-Ting HuangFang-Ju LinPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 5, p e0252124 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Chih-Ning Cheng Shang-Yi Huang Pei-Wen Lien Shih-Ting Huang Fang-Ju Lin Survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan.
description	<h4>Background</h4>We aimed to provide real-world information on survival, health care resource utilization (HCRU), and expenditures related to various first lines of therapy (1LOTs) in newly diagnosed multiple myeloma (NDMM) patients who were transplant ineligible (TI).<h4>Patients and methods</h4>From the Taiwan National Health Insurance Database (2008-2016), we identified 1,511 NDMM-TI patients who had received 1LOT since June 2012. We categorized 1LOT regimens into four groups: bortezomib (V)+thalidomide (T), V, T, and non-V/T. Patients' characteristics were collected. The overall survival (OS), event-free survival (EFS), frequencies of HCRU (hospitalization, visiting outpatient and emergency departments), and related expenditures within one year after commencement of the 1LOT were evaluated and compared.<h4>Results</h4>The mean age of the included patients was 71.3 (SD 10.7) years, and 40.4% of patients had a CCI score ≥3. Most patients (747; 49.4%) were in the V+T group and, after adjusting for covariates, had a significantly longer OS (median, 22.2 months) and EFS (9.1 months) than those in the T group (12.6 and 4.5 months, respectively) and the non-V/T group (12.2 and 3.2 months, respectively), but they were mostly comparable with patients in the V group (23.8 and 6.6 months, respectively). Compared to those in the V+T group, patients in the T and non-V/T groups had 29% and 39% fewer outpatient visits and 15% and 24% lower total expenditure, respectively.<h4>Conclusion</h4>Our real-world data consolidate evidence for the effectiveness of bortezomib-containing regimens as the 1LOT in NDMM-TI patients at the expense of more outpatient visits and higher total costs.
format	article
author	Chih-Ning Cheng Shang-Yi Huang Pei-Wen Lien Shih-Ting Huang Fang-Ju Lin
author_facet	Chih-Ning Cheng Shang-Yi Huang Pei-Wen Lien Shih-Ting Huang Fang-Ju Lin
author_sort	Chih-Ning Cheng
title	Survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan.
title_short	Survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan.
title_full	Survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan.
title_fullStr	Survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan.
title_full_unstemmed	Survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan.
title_sort	survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in taiwan.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/3fa55435c6784a3ea480b905293d03fe
work_keys_str_mv	AT chihningcheng survivalhealthcareresourceutilizationandexpendituresoffirstlinetreatmentsformultiplemyelomapatientsineligiblefortransplantintaiwan AT shangyihuang survivalhealthcareresourceutilizationandexpendituresoffirstlinetreatmentsformultiplemyelomapatientsineligiblefortransplantintaiwan AT peiwenlien survivalhealthcareresourceutilizationandexpendituresoffirstlinetreatmentsformultiplemyelomapatientsineligiblefortransplantintaiwan AT shihtinghuang survivalhealthcareresourceutilizationandexpendituresoffirstlinetreatmentsformultiplemyelomapatientsineligiblefortransplantintaiwan AT fangjulin survivalhealthcareresourceutilizationandexpendituresoffirstlinetreatmentsformultiplemyelomapatientsineligiblefortransplantintaiwan
_version_	1718375475549569024

Survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan.

Ejemplares similares